NICM
APGE

Neo Ivy Capital Management’s Apogee Therapeutics APGE Stock Holding History

Neo Ivy Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
+9,798
New +$883K 0.3% 124
2026
Q1 		– Sell
-10,910
Closed -$823K – 333
2025
Q4 		$823K Buy
+10,910
New +$687K 0.13% 183
2025
Q1 		– Sell
-38,523
Closed -$1.75M – 283
2024
Q4 		$1.75M Buy
+38,523
New +$1.96M 0.35% 123

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Neo Ivy Capital Management's APGE Position: Q2 2026 in Review

Neo Ivy Capital Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 9,798 shares worth $1.3M. The stake represents 0.3% of the portfolio and ranks #124 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in APGE as recently as Q4 2025.

Neo Ivy Capital Management first reported a position in APGE in Q4 2024 and has held it in 3 quarters since. The position peaked at $1.75M in Q4 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Neo Ivy Capital Management held 9,798 shares of Apogee Therapeutics worth $1.3M as of Q2 2026.
  • Apogee Therapeutics was a new Neo Ivy Capital Management position in Q2 2026.
  • Apogee Therapeutics made up 0.3% of Neo Ivy Capital Management's portfolio in Q2 2026, its #124 holding.
  • Neo Ivy Capital Management first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Neo Ivy Capital Management's Apogee Therapeutics position peaked at $1.75M in Q4 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.